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Abstract (Words = 249) 
Purpose 
The 21-gene recurrence score (Oncotype DX) (RS) informs systemic therapy decision making in ER-
positive HER2-negative early breast cancer (BC). To date no study has described the more nuanced 
discussions that take place around systemic therapy decision making or the impact of the RS on 
concordance in such decision making. Here we utilized a novel decision making tool to assess the 
impact of the RS on decision making as well as concordance of treatment recommendations.  
Patients and Methods 
The clinicopathological information (CPI) of 50 BCs without and with the RS were presented to a panel 
of breast oncologists. The Liverpool Adjuvant Systemic Therapy Decision Tool (LASTDT) was developed 
and used to categorize treatment recommendations for each case. Outcome measures included the 
impact of the RS on decisiveness, and concordance in decision making and its impact on treatment 
recommendations. 
Results 
Availability of the RS increased definitive decision making from 8% (4/50) to 56% (28/50) [2=79.35, 
p<0.001] and altered the LASTDT category in 68% (34/50) of cases (p<0.001), 74% of which were to 
forgo chemotherapy. With knowledge of the RS, universal concordance rose from 14% to 64% 
[K=0.328: K=0.729].  
Conclusions 
The RS improves certainty of decision making as well as concordance amongst oncologists. This 
provides evidence that the availability of the RS can improve consistency of decision making amongst 
oncologists and thus helps to ensure patients are managed consistently. This is particularly important 
when patients are managed in a loco-regional, multidisciplinary team manner where heterogeneous 
decisions can lead to disparity in care.  
  
Introduction (words = 2650) 
The widespread use of adjuvant polychemotherapy in the treatment of early breast cancer has 
improved survival [1].  However, any benefits need to be weighed against both short and long term 
toxicities, as well as the impact on quality of life. As such there remains a population of women with 
ER-positive, HER2-negative, node-negative BC where treatment recommendations with regard to 
chemotherapy remain unclear.  
The 21-gene recurrence score (RS) assay (Oncotype DX assay; Genomic Health, Redwood City, CA),  is 
a genomic classifier which has been validated as a prognosticator [2] and a predictor of the likelihood 
of chemotherapy benefit in ER positive, HER2 negative early invasive breast cancer [3]. The 21-gene 
RS has been validated by multiple studies including The National Surgical Adjuvant Breast and Bowel 
Project (NSABP) B-14 trial [2] and the NSABP trial B20 trial [1,3]. These data revealed that most of the 
benefit of adjuvant chemotherapy was restricted to tumours with a high RS who had a 28% absolute 
decrease in 10-year distant recurrence rate, as compared to minimal, if any, benefit in tumours with 
a low RS [3]. A clinically important benefit rate could not be excluded in the intermediate RS group 
estimate [3]. More recently, TAILORx has demonstrated that in this intermediate RS group there is no 
additional benefit is in the addition of chemotherapy to endocrine therapy [4].  
 Internationally it has been shown that the RS impacts significantly on decision making and alters 
treatment away from chemotherapy and endocrine therapy to endocrine therapy alone in a significant 
number of cases (Table S1) [5-10]. In a retrospective, non-MDT based, study a 63% reduction in 
chemotherapy usage in patients with intermediate risk early breast cancer was demonstrated [11]. In 
addition, a meta-analysis across 15 different countries showed that RS has a significant impact on 
decision making with an alteration in treatment recommendation in 30% of cases and a 16% reduction 
in the use of adjuvant chemotherapy [6].  
Four studies have explored the use of the RS in the MDT environment, three of which found that the 
RS altered treatment decisions and the majority of those away from chemotherapy [12-15]. Of note, 
Spellman et al [15] suggests that the RS score may, in fact, complicate the discussion in a 
multidisciplinary team (MDT) setting given the difference of opinion amongst specialists regarding the 
RS score, its reliability and utility.  
Whilst two studies concluded that the RS improved clinician confidence in decision making [14,15], no 
studies to date have investigated the impact of the RS on concordance of decision making amongst 
oncologists. Furthermore, none of the studies attempted to reflect the more nuanced decision making 
scenarios that exist in early ER+ BC regarding chemotherapy particularly in the intermediate RS group 
[12-15]. 
The aim of the present study, was to evaluate systemic therapy decision making by a group of 
oncologists and the influence of 21-gene RS, as well as concordance of decision making between them 
when using the clinicopathological information available within a routine MDT, and the effect on 
decision making when this information was presented with and without the RS. Furthermore, to 
reflect the real life uncertainty that exists with regard to systemic therapy decision in ER-positive, 
HER2-negative BC, the Liverpool Systemic Therapy Adjuvant Decision Tool was designed and utilized 
to record decisions.   
  
 Materials and Methods 
Patients 
Breast cancer cases that were discussed at MDTs between November 2012 and November 2014 in 
two acute NHS hospital trusts (Royal Liverpool and Broadgreen University Hospitals NHS Trust and St 
Helens and Knowsley Teaching Hospitals NHS Trust) and where a decision was made to request the RS 
were identified. 
Expert Panel Review 
Clinicopathological information (CPI) for these cases was collected, including age, pathological size, 
grade, ER positivity as defined by the Allred score, HER2 status, Ki67, the presence or absence of 
vascular invasion, nodal status and margins.  These anonymized data were summarized for each 
patient twice once without the RS and once with the RS. The cases were then blindly reviewed in the 
study MDT in a random order by a panel of five consultant oncologists specializing in breast cancer. In 
each instance, each member of the panel used the Liverpool Adjuvant Systemic Therapy Decision Tool 
(LASTDT) to make a treatment recommendation prior to the availability of the RS (pre-RS) and after 
the availability of the RS (post-RS) (figure 1). 
The Liverpool Adjuvant Systemic Therapy Decision Tool (LASTDT)  
The LASTDT was designed to reflect decision making in the context of an MDT with regard to ER-
positive, HER2-negative breast cancer and consists of four categories: (1) endocrine therapy alone 
(Erec); (2) chemotherapy therapy recommended (Crec); (3) chemotherapy discussion with preference 
towards recommendation of chemotherapy (Cdis) and (4) chemotherapy discussion with a preference 
towards recommendation of endocrine therapy alone (Edis). 
The study was registered as an audit with the Clatterbridge Cancer Centre (Audit No 123). 
Study Outcomes 
The primary aim of the study was to ascertain amongst a panel of oncologists the impact of the RS on 
treatment decision making including decisiveness as defined Erec or Crec. The secondary outcomes 
included the degree to which treatment decision making was stratified by RS and the degree of 
concordance in decision. All outcomes were measured using the LASTDT. 
Statistical Analysis 
Summation Score 
Once the treatment recommendation had been made for each case by each oncologist before and 
after the RS the decision, decisions based on the LASTDT were used to produce a summation score of 
consultant decision-making (figure 2). The summation score is cumulative and results in a scale from 
-10 (all consultants agree on ERec) to 10 (all consultants agree on CRec). All values less than 0 would 
be towards not having chemotherapy but at least one consultant would recommend seeing the 
patient (EDis). If the score is more than 0 it means that at least a discussion would occur regarding 
chemotherapy in addition to endocrine therapy (CDis).  
Statistical Methods 
Continuous variables are presented with their median and interquartile range (IQR), while categorical 
variables are described as frequency of counts and percentages. Profile plots were produced as a 
graphical representation of changes in summation score between the pre- and post-RS decisions and 
scatter plots with Spearman correlation coefficient uses to measure the association between the RS 
and summation scores.  Differences in treatment decisions as a result of knowledge of the to RS were 
assessed using McNeamar and Fleiss’ Kappa with 95% confidence intervals (CIs) used for assessing the 
degree of agreement across the oncologists for both pre and post RS treatment decisions. Statistical 
analyses were performed with RStudio version 1.0.143, SPSS version 23 and Microsoft Excel 2010. 
Results 
Clinico-pathological characteristics and recurrence score data 
Between November 2012 and November 2014 fifty patients ER- positive, HER2-negative BC were 
identified where the RS was requested following discussion within the MDT meeting. CPI of these 
cases are summarized in Table 1. The median age of the cohort was 56 (range 31-76; IQR 51.25-63), 
and median size of tumour 30mm (range 7-70mm; IQR 19.25-32.75) (Figure S2). Ki67 was available in 
all cases with a mean Ki67 of 29% (range 7-70%). With regard to the in the axillary lymph nodes 22% 
(11/50) and 6%(3/50)  had micrometastasis and macrometastasis respectively (table 1,figure S3a). The 
median RS result was 16.5 (range 2-55; IQR 12-21) distributed as follows: 42% (21/50) low, 48% 
(24/50) intermediate, and 10% (5/50) high.  
Impact of recurrence score on treatment recommendation and decisiveness of decision-making 
Using the LASTDT to categorize decision making and with the CPI alone the following 
recommendations were made: Erec 6% (3/50), Crec 2% (1/50), Edis 50% (25/50), Cdis 42% (21/50). 
When the RS was added to the same CPI. In the following recommendations were made Erec 46% 
(23/50), Crec 10% (5/50), Edis 26% (13/ 50) and Cdis 18% (9/50).   
Comparing the decisions with CPI alone and with the CPI plus the RS there was a decrease in the 
number of cases within the Edis and Cdis groups and an increase in definitive decision making from 
8% (4/50) to 56% (28/50) [2=79.35, p<0.001]. There was a clear move towards endocrine therapy in 
50% (25/50) of cases with a move from chemotherapy to endocrine therapy (Cdis to Edis/Erec) in 26% 
(13/50) cases and from Edis to Erec in a further 24% (12/50). Combining CPI and RS resulted in more 
definitive decision making as evidenced by the increase in Crec from 2% (1/50) to 10% (5/50) and an 
increase in Erec  6% (3/50) to 46% (23/50) (Figure 3, S4, S5). Figures 4a, 4b and S5 illustrate the 
outcomes for individual patients and their treatment recommendation based on the summation score 
before and after the RS. 
Correlation of RS and treatment recommendations  
Scatter plots of RS against summation score using the LASTDT show that there is no correlation when 
treatment decision making is based on CPI alone (figure 5a) but that there is a strong correlation 
between knowledge of the RS and decision making [ρ=0.928, p<0.001] (Figure 5b). 
Impact of RS on nature of oncology referral 
The nature of the out-patient consultation when an MDT decision is made to recommend 
chemotherapy (Crec) or to discuss chemotherapy (Cdis and Edis groups) is very different in terms of 
information provision and discussion as compared to one wheN when endocrine therapy alone (Erec) 
is recommend. Within this study, with CPI alone, 94% (47/50) of patients would have been referred 
for an appointment where chemotherapy would have been discussed either with a clear 
recommendation (Crec) 2% (1/50) or for a discussion (Cdis and Edis)  92% (46/50) falling within the 
(Cdis and Edis). However, the addition of the RS resulted in a decrease in the number of patients being 
referred to discuss chemotherapy 54% (27/50), with the number within Cdis and Edis decreased to 
only 28% (14/50). The correlation between RS and treatment recommendation was significant (Figure 
5a&b) [ρ=0.928, p<0.001]. 
 
Concordance in decision making between oncologists 
With CPI alone concordance amongst all participating oncologists occurred in only 14% of cases the 
addition of the RS this increased this to 64% (figure 6).  The initial level of agreement across the panel 
[K=0.328 (95%CI 0.220-0.437)] increased by 1.2 fold (120%) after the disclosure of RS information 
[K=0.729 (95%CI 0.632-0.827)]. In addition, the decision-wise Kappas differed between pre and post 
RS assessment demonstrating an increase in definitive decision making (Table 2). 
  
 Conclusions  
This study explored decision making regarding use of adjuvant chemotherapy in ER-positive, HER2-
negative breast cancer with and without 21-gene recurrence score, utilising a novel tool to document 
decision making, the so-called Liverpool Adjuvant Systemic Therapy Decision Tool (LASTDT). The tool 
was designed to record decision making with regard to systemic therapy in this group and to reflect 
that decision making in the real world is not always a binary, given the uncertainty of the benefit of 
chemotherapy in ER-positive, HER2-negative node negative breast cancer. This uncertainty existed at 
the time of the study given the lack of data regarding the benefit of chemotherapy within the 
intermediate RS group [11]. LASTDT in addition to the two clear decisions of endocrine therapy alone 
or endocrine therapy plus chemotherapy allows for two other decisions; namely a discussion 
regarding adjuvant chemotherapy with a preference either towards or against a recommendation of 
chemotherapy following a discussion with the patient. 
The published literature has previously illustrated that the availability of the RS impacts and alters 
adjuvant decision making regarding systemic therapy in 20% of cases [6] and more often than not this 
is to recommend to omitting chemotherapy rather than to recommending it [16], with a reduction in 
the use of chemotherapy (table S1,S2). The results reported in this study are consistent with these 
published data, with alteration in the recommended treatment occurring in 67% of cases, with the 
majority of these to omit adjuvant chemotherapy. 
However, previous studies do not address the more nuanced issues around the intermediate group 
and do not appreciate the presence of a ‘grey-area’ in decision making with regard to the intermediate 
RS group present at the time of the study. For example, within the SAKK25/10 study the decision made 
by the MDT with knowledge of the RS was binary: either endocrine therapy (ET) or chemotherapy plus 
endocrine therapy (CT + ET) [17]. Furthermore, other studies have assumed that without a RS result, 
all patients would have received chemotherapy, which does not necessarily reflect the real world 
clinical scenario; with no recording of the discussion at MDTs without the RS [11]. One study recorded 
physician’s confidence in treatment recommendation before and after the RS, based on answers to “I 
am confident in my treatment recommendation prior to ordering Oncotype DX” [18]. In this study, 
availability of the RS appeared to reduce the percentage of physicians who agreed/strongly agreed 
from 96% (pre-assay) to 90% (post-assay), although CT recommendations decreased from 52.1% to 
37.7% [18]. Similarly in a Canadian population-based cohort study a pre-test category of “unsure” 
(whether chemotherapy should be given) was included and this group accounted for 328 of 508 
patients (65%) who had a change in recommendation [16]. 
Within this study the LASTDT allows the ‘grey area’ to be recorded and it clearly demonstrates that 
the majority of cases prior to the availability of the RS sit within the Cdis and Edis ie a discussion with 
a preference to recommending or not chemotherapy. This would have entailed a detailed discussion 
of the risk of relapse with patient and the potential benefit of chemotherapy in reducing this risk as 
well as its side effects. This is not only resource intense but may lead to anxiety for patients [15]. The 
addition of the RS to CPI resulted in a significant reduction in the number of patients within the 
Cdis/Edis group, demonstrating that it provides oncologists with the reassurance to make decisive and 
definitive treatment recommendations: more often, this was to endocrine therapy alone. While this 
study did not aim to formally quantify or cost time and resource saved in the context of consultation 
time or benefits to patients, it is likely that the RS led to a more efficient use of oncological resource 
allowing more focused and definitive discussions to take place. This is likely also to have led to less 
uncertainty and anxiety overall in the intermediate RS group [15]. 
Another key impact of the availability of the RS that is demonstrated by this study is the increased 
concordance in decision making amongst a group of experienced oncologists. It is clearly seen that 
with the CPI alone concordance in decision making was not very strong, reflecting differences in views 
regarding the use and benefit of chemotherapy in individual cases. However, the addition of the RS 
results in a dramatic change with a highly significant correlation between RS and decisions made. It is 
of interest that concordance in decision making reduces for those BC with a RS of 20-29, reflecting the 
real life uncertainty at the time in the absence of the results from the TAILORX study [4].  If these 
observations were to be translated and generalised into the setting of an MDT it would mean more 
unanimity in decision making, and more standardisation of treatment decisions regarding the use or 
not of chemotherapy. 
Strengths of the current study include that it was carried out in a blinded fashion using real patient 
data with each consultant recording data independently. Weaknesses include that the study was 
retrospective and the impact of the decisions on actual treatment in the clinic was not measured. 
In conclusion, the current study supports the previously published data in demonstrating that the 
availability of the RS results in a reduction in chemotherapy use. By utilising a novel decision making 
tool to record more nuanced decision making we have for the first time demonstrated that the RS not 
only enables more definitive decision making by individual oncologists but also significantly improves 
concordance of decision-making amongst the same a group of oncologists with all the benefits that 
follow from this. The LASTDT could be used and/or adapted for further impact assessment studies 
regarding the effects of the introduction of genomic assays/information in the management of breast 
cancer. 
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